GSK-4069327A is under clinical development by LimmaTech Biologics and currently in Phase II for Bacillary Dysentery (Shigellosis). According to GlobalData, Phase II drugs for Bacillary Dysentery (Shigellosis) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GSK-4069327A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GSK-4069327A overview

GSK-4069327A (GVXN-SD133) is under development for the prophylaxis for Shigella diarrhoea caused by Shigella dysenteriae. It is a biconjugate tetravalent vaccine. The vaccine candidate is administered intramuscularly. GVXN SD133 vaccine is developed based on bioconjugate vaccine technology.

LimmaTech Biologics overview

LimmaTech Biologics is a clinical-stage biopharmaceutical company focused on the development and manufacturing of novel therapeutic proteins or bioactive molecules. The company conducts clinical trials on shigella bacteria to help prevent diarrheal diseases and Klebsiella studies to prevent klebsiella infections. LimmaTech Biologics’ proprietary bioconjugation platform also enables the research and development of innovative vaccines for a wide range of disease indications. The company specializes in vivo carbohydrate engineering to develop drugs for both the treatment and prevention of life-threatening diseases. It seeks to work in partnership with other pharmaceutical companies for research and development of bioconjugates as vaccines. LimmaTech Biologics is headquartered in Zurich, Switzerland.

For a complete picture of GSK-4069327A’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.